|
J Biol Chem, Vol. 273, Issue 43, 28305-28313, October 23, 1998
Induction of Murine Macrophage Growth by Oxidized Low Density
Lipoprotein Is Mediated by Granulocyte Macrophage
Colony-stimulating Factor*
Takeshi
Biwa §,
Hideki
Hakamata ,
Masakazu
Sakai§,
Akira
Miyazaki ,
Hiroshi
Suzuki¶,
Tatsuhiko
Kodama ,
Motoaki
Shichiri§, and
Seikoh
Horiuchi **
From the Department of Biochemistry and
§ Department of Metabolic Medicine, Kumamoto University
School of Medicine, Kumamoto 860-0811, ¶ Chugai Pharmaceutical Co.
Ltd., Shizuoka 412-0038, and Department of Molecular Biology and
Medicine, Research Center for Advanced Science and Technology,
University of Tokyo, Tokyo 153-0041, Japan
 |
ABSTRACT |
We have examined whether certain secreted
factor(s) is involved in oxidized low density lipoprotein
(Ox-LDL)-induced murine macrophage growth. An antibody against
granulocyte-macrophage colony-stimulating factor (GM-CSF) effectively
inhibited Ox-LDL-induced macrophage growth by >80%. Ox-LDL as well as
phospholipase A2-treated acetylated LDL enhanced
mRNA levels and protein release of GM-CSF from macrophages, while
neither acetylated LDL nor lysophosphatidylcholine (lyso-PC) showed
such effects. The maximal induction of GM-CSF by Ox-LDL was noted at
4 h, followed by a time-dependent decrease to a basal
level within 24 h. Ox-LDL-induced macrophage growth was inhibited
by 75% by replacement of the culture medium at 24 h by a fresh
medium containing the same concentration of Ox-LDL, when GM-CSF had
already returned to the basal level. Thus, a cytokine(s) other than
GM-CSF is also expected to participate in Ox-LDL-induced macrophage
growth in a later phase. The Ox-LDL-induced GM-CSF release was
inhibited by calphostin C, a protein kinase C inhibitor, and was
significantly reduced in macrophages from the knockout mice lacking
class A, type I and type II macrophage scavenger receptors
(MSR-AI/AII). These results taken together indicate that effective
endocytosis of lyso-PC of Ox-LDL by macrophages through MSR-AI/AII and
subsequent protein kinase C activation have led to GM-CSF release into
the medium which may play a priming role in conjunction with other
cytokines in Ox-LDL-induced macrophage growth.
 |
INTRODUCTION |
Macrophage-derived foam cells, a characteristic feature of the
early stages of atherosclerosis, play a crucial role in the development
of atherosclerotic lesions (1). Macrophages are known to take up
chemically modified low density lipoproteins (modified
LDLs)1 such as acetylated LDL
(acetyl-LDL) and oxidized LDL (Ox-LDL) through the scavenger receptor
pathway (2, 3) and become foam cells. It is generally accepted that LDL
is oxidatively modified by cells of arterial walls such as smooth
muscle cells, endothelial cells, and macrophages, and is converted to a
ligand for the macrophage scavenger receptors (MSR) (3). Among
chemically modified LDLs, Ox-LDL is thought to be the most likely
candidate as an atherogenic lipoprotein in vivo because of
its presence in human and rabbit atherosclerotic plaques (4, 5). In
addition, in vitro experiments using cultured
monocytes/macrophages have demonstrated the potential atherogenic
effects of Ox-LDL such as chemotactic activity for monocytes (6),
enhancement of monocyte adhesion to endothelial cells (7), initiation
of monocyte differentiation into macrophages (8), inhibition of
migration of tissue macrophages (9), and induction of macrophage cell
death (10).
We have previously demonstrated a growth-stimulating effect of Ox-LDL
in vitro on several types of macrophages, such as murine peritoneal macrophages (11, 12), rat peritoneal macrophages (13), and
human blood monocyte-derived macrophages (14). Since previous
morphological reports demonstrated that macrophage-derived foam cells
proliferated in situ in atherosclerotic lesions (15-17), it
seems reasonable to expect that the Ox-LDL-induced macrophage growth is
linked to the development of atherosclerotic lesions. Therefore, it is
important to characterize the molecular cascade(s) involved in the
induction of macrophage growth by Ox-LDL. Our previous studies
demonstrated that the specific uptake of lysophosphatidylcholine (lyso-PC) of Ox-LDL by class A, type I and type II MSR (MSR-AI/AII) was
essential for Ox-LDL-induced macrophage growth (12, 14, 18), in which
activation of protein kinase C (PKC) is involved (19). Recently,
Martens et al. (20) reported that activation of
phosphatidylinositol-3-OH kinase is involved in the induction of
macrophage growth by Ox-LDL. However, the molecular cascade(s) leading
to Ox-LDL-induced macrophage proliferation is still not fully
understood.
There are two possible mechanisms for macrophage proliferation induced
by Ox-LDL. One is that Ox-LDL-induced mitogenic stimulus directly leads
to macrophage proliferation. The other is that Ox-LDL stimulates the
induction of certain growth factor(s) which leads to macrophage growth.
Three types of cytokines are known to exhibit growth stimulating
activity for macrophages. These include the macrophage
colony-stimulating factor (M-CSF) (21, 22), granulocyte-macrophage
colony-stimulating factor (GM-CSF) (23, 24), and interleukin-3 (IL-3)
(25). In the present study, we determined whether a soluble factor(s)
is involved in the Ox-LDL-induced macrophage growth. The results
indicated that Ox-LDL-induced GM-CSF release from macrophages may play
a priming role in macrophage growth.
 |
EXPERIMENTAL PROCEDURES |
Materials --
All reagents for cell culture were obtained
from Life Technologies, Inc.
[methyl-3H]Thymidine (80 Ci/mmol),
[ -32P]dCTP (370 MBq/ml), and Hybond-N+
nylon membrane were purchased from Amersham. Recombinant murine IL-3
and recombinant murine IL-5 were purchased from Research and
Diagnostics Systems. Recombinant murine M-CSF was purchased from
Upstate Biotechnology Inc. Recombinant murine GM-CSF was purchased from
Genzyme. Goat polyclonal neutralizing antibodies against cytokines such
as murine IL-3, murine IL-5, murine M-CSF, and murine GM-CSF were
purchased from Research and Diagnostics Systems. ELISA kit for
determination of GM-CSF level was purchased from Amersham.
Phospholipase A2 (PLA2) from Crotalus
atrox venom, calphostin C, and palmitoyl-lysophosphatidylcholine
were purchased from Sigma. Calphostin C was stored at 20 °C as
stock solutions of 500 µM in dimethyl sulfoxide and used
within 1 week of dissolving. The final concentrations of dimethyl
sulfoxide were less than 0.1% in the culture medium, which did not
affect cell viability and macrophage growth. Calphostin C at <500
nM did not show any cytotoxic effect when assessed by
lactate dehydrogease release. Other chemicals were the best grade
available from commercial sources.
Lipoproteins and Their Modifications--
Human LDL
(d = 1.019 to 1.063 g/ml) was isolated by sequential
ultracentrifugation from the plasma of normolipidemic subjects after
overnight fasting (26). LDL was dialyzed against 0.15 M
NaCl and 1 mM EDTA (pH 7.4). Acetyl-LDL was prepared by
chemical modification of LDL with acetic anhydride (26). Acetyl-LDL was dialyzed against phosphate-buffered saline and treated with
PLA2 as described by Quinn et al. (6) with minor
modifications (12). Seventy-five percent of phosphatidylcholine in
PLA2-treated acetyl-LDL was converted to lyso-PC. Ox-LDL
was prepared by incubation of 0.1 mg/ml LDL with 5 µM
CuSO4 in phosphate-buffered saline for 20 h at
37 °C followed by the addition of 1 mM EDTA, cooling on ice, and dialysis against 0.15 M NaCl and 1 mM
EDTA (pH 7.4) (12). Protein concentrations were determined by BCA
protein assay reagent (Pierce) using bovine serum albumin as a
standard, and were expressed as milligrams of protein/ml (27). The
levels of endotoxin associated with these lipoproteins were <1 pg/µg
of protein; these were measured by a commercially available kit
(Toxicolor system, Seikagaku Corp.). Moreover, macrophage growth was
not induced by endotoxin at a concentration <1 ng/ml in our
experimental system.
Cell Culture --
Unless otherwise specified, cell culture
experiments were performed at 37 °C in 5%
CO2. Peritoneal macrophages were collected from
four different mice; those from non-stimulated male DDY mice (25-30
g), those from double-knockout mice lacking both the Fc receptor chain, and the class II Fc receptor for immunoglobulin G
(FcR /Fc RII) (Taconic Farms, Inc.) (28, 29), those from MSR-AI/AII-knockout mice (30), and those from their wild-type littermates. These peritoneal macrophages were collected with 8 ml of
ice-cold phosphate-buffered saline and suspended in RPMI 1640 medium
(Nissui Seiyaku Co., Tokyo) supplemented with 10% heat-inactivated
newborn calf serum (Life Technologies, Inc.), streptomycin (0.1 mg/ml),
and penicillin (100 units/ml) (medium A). Cell suspensions were
dispersed in each well of appropriate tissue culture plates and
incubated for 90 min. Nonadherent cells were removed by washing three
times with medium A. After washing, cell number was decreased to
~80%. More than 98% of adherent cells were judged to be macrophages
by Giemsa staining. The macrophage monolayers thus formed were used for
following cellular experiments.
SR-4987 cells, a murine bone marrow-derived stromal cell line, were
obtained from American Type Culture Collection (ATCC) (31) and cultured
in McCoy's 5a medium (Life Technologies, Inc.) supplemented with 10%
heat-inactivated fetal calf serum. WEHI-3 cells, a murine
myelomonocytic leukemia cell line, were obtained from ATCC (32) and
cultured in RPMI 1640 medium (Nissui Seiyaku Co., Tokyo) supplemented
with 10% heat-inactivated fetal calf serum.
Tritiated Thymidine Incorporation Assay--
The macrophage
monolayers (5 × 104 cells/well in 24-well tissue
culture plates (15.5 mm in diameter, Corning)) formed were cultured
with 1 ml of medium A in the presence of the lipoproteins to be tested
without medium exchange unless otherwise specified. [3H]Thymidine incorporation assay was performed as
described previously (12) with the following minor modifications.
Eighteen hours before the termination of the experiments, 20 µl of 50 µCi/ml [3H]thymidine was added to each well and
incubated for 18 h. After discarding the medium, each well was
washed three times with 1 ml of phosphate-buffered saline and the cells
were lysed with 0.5 ml of 0.5 M NaOH by incubation on ice
for 10 min. The cell lysates were neutralized with 0.25 ml of 1 M HCl, further precipitated with 0.25 ml of 40%
trichloroacetic acid by incubation on ice for 20 min. The resulting
trichloroacetic acid-insoluble material was collected on filters
(Millipore PVDF filter; 0.45 µm in pore size) and washed three times
with 1 ml of 99.5% ethanol. The filters were dried under air and their
radioactivity was counted in a liquid scintillation spectrophotometer
(11).
Cell Counting Assay--
The macrophage monolayers (5 × 104 cells/well in 24-well tissue culture plates) as
described above were cultured with 1 ml of medium A in the presence of
the lipoproteins to be tested. After incubation for 7 days (without
medium exchange unless otherwise specified), the adherent cells within
five standard-sized areas (0.5 × 0.5 mm) in triplicate wells were
counted as described previously (33). Then, the cells were lysed in 1%
(w/v) Triton X-100, and the naphthol blue-black-stained nuclei were
counted in a hemocytometer as described previously (11).
Enzyme-linked Immunosorbent Assay (ELISA) for GM-CSF--
The
macrophage monolayers (5 × 106 cells/plate, 10 cm in
diameter, Falcon) formed were cultured in 15 ml of medium A with or without the lipoproteins to be tested. During incubation for 120 h, 300 µl of the medium were collected at various time intervals (the
actual incubation times were: 0, 2, 4, 6, 12, 24, 48, 72, and 120 h) and immediately centrifuged at 10,000 × g for 1 min to remove any particulate material. The supernatant was stored at
80 °C immediately. After all culture experiments were completed, the frozen culture supernatants were quickly thawed to determine GM-CSF
levels in the medium. The concentration of GM-CSF protein was
determined according to the instructions provided by the manufacturer of GM-CSF-specific ELISA system (sensitivity, 5 pg/ml, Amersham) using
recombinant murine GM-CSF as a standard.
RT-PCR and Northern Blot Analyses--
Standard molecular
biology techniques were used (34). After incubation of murine
peritoneal macrophage monolayers (2 × 106 cells/well
in 6-well plate, 3.5 cm in diameter, Nunc) with Ox-LDL (0 to 40 µg/ml) for different time intervals (0 to 7 h), total RNA was
extracted with TRIzol (Life Technologies, Inc). Total RNAs of SR-4987
cells (31) and WEHI-3 cells (35) were also extracted with TRIzol. The
first strand cDNA synthesis containing 1 µg of total RNA was
primed with oligo(dT). Primers used for PCR amplification of GM-CSF,
M-CSF, IL-3, IL-5, and -actin were designed on the basis of murine
GM-CSF cDNA (36), murine M-CSF cDNA (37), murine IL-3 cDNA
(38), murine IL-5 cDNA (39), and murine -actin cDNA (40)
sequences as follows: for GM-CSF, forward primer,
TGTGGTCTACAGCCTCTCAGCAC (nucleotides 64 to 86 of murine GM-CSF coding
sequence) and reverse primer, CAAAGGGGATATCAGTCAGAAAGGT (nucleotide 407 to 431 of murine GM-CSF coding sequence) (36); for M-CSF, forward
primer, GTGTCAGAACACTGTAGC (nucleotide 103 to 120 of murine M-CSF
coding sequence) and reverse primer, TGAGAATCATCCCAAGCC (nucleotide 663 to 680 of murine M-CSF coding sequence) (37); for IL-3, forward primer,
GCTTCAATCAGTGGCCGGGATACCCAC (nucleotide 79 to 105 of murine IL-3 coding
sequence) and reverse primer, TTAACATTCCACGGTTCCACGGTTA (nucleotide 477 to 501 of murine IL-3 coding sequence) (38); for IL-5, forward primer,
GACAAGCAATGAGACACGATGAGG (nucleotide 129 to 152 of murine IL-5 coding
sequence) and reverse primer, GAACTCTTGCAGGTAATCCAGG (nucleotide 342 to
363 of murine IL-5 coding sequence) (39); for -actin, forward
primer, GTGGGCCGCTCTAGGCACCAA (nucleotide 25 to 45 of murine -actin
coding sequence) and reverse primer, CTCTTTGATGTCACGCACGATTTC
(nucleotide 541 to 564 of murine -actin coding sequence) (40); the
sizes of RT-PCR products of GM-CSF, M-CSF, IL-3, IL-5, and -actin
were expected to be 368, 578, 423, 235, and 540 base pairs,
respectively. The cycling conditions in the GeneAmp 9600 System
consisted of a first step of 94 °C denaturation for 10 min, followed
by 35 cycles of annealing at 54 °C for 60 s, extension at
75 °C for 90 s, and denaturation at 94 °C for 30 s,
with a final elongation step at 75 °C for 10 min. Amplification
products were analyzed by 1.5% agarose gel electrophoresis. To verify
that the amplification products was consistent with the reported
sequences of murine GM-CSF, M-CSF, IL-3, IL-5, and -actin, they were
ligated into pGEM-T (from Promega), transfected into Escherichia
coli XL1-Blue and sequenced by using 373A DNA sequencer (Applied
Biosystems).
For Northern blot analysis, GM-CSF cDNA inserted into pGEM-T was
excised by restriction enzyme ApaI and SacI, and
labeled with [ -32P]dCTP by random nanomer primer
method using MegaprimeTM DNA labeling system (Amersham)
(41). After incubation of murine peritoneal macrophage monolayers
(2 × 106 cells/well in 6-well plate, 3.5 cm in
diameter, Nunc) with 40 µg/ml Ox-LDL for 1 h, total RNA was
prepared from 5 dishes with TRIzol. Ten µg/lane of total RNA was
fractionated by electrophoresis through a denaturing formaldehyde 1%
agarose gel, transferred to Hybond-N+ nylon membrane as
described (41) by capillary transfer with 10 × SSC for 20 h,
and then cross-linked by UV (FS 1500, Funakoshi). Hybridization of the
membrane with 32P-labeled probe specific for GM-CSF was
performed in a solution containing Hybridization buffer tablets
(Amersham) with 50% formamide, 0.1 mg/ml salmon sperm DNA at 42 °C
as described previously (41). Stringent washing of the membrane was
performed with 0.2 × SSC, 0.1% SDS at a higher temperature (from
42 to 65 °C) (41). The membrane was then exposed to a Fuji Imaging
Plate BAS-III (Fuji Photo Film Co.) for 2 h at room temperature
and analyzed using a BAS-2000 II (Fuji X).
Assay of PKC Activity--
PKC activity of macrophages was
assayed by MESACUP Protein Kinase Assay Kit (Medical and Biological
Laboratories) as described previously (19). The macrophage monolayers
(5 × 106 cells/plate, 10 cm in diameter, Falcon)
formed were cultured for the indicated times in 15 ml of serum-free
RPMI 1640 with or without the lipoproteins to be tested. Cells were
detached from the wells and homogenized by sonication for 30 s at
4 °C with Sonifier (Branson Sonic Power Co). The membrane fractions were collected by ultracentrifugation and were used in the PKC assay as
described previously (19).
Statistical Analysis--
Data were expressed as mean ± S.D. Differences between groups were evaluated by the Student's
t test. When the p value was less than 0.05, the
difference was considered significant.
 |
RESULTS |
Effect of Medium Exchange on Ox-LDL-induced Macrophage
Growth--
To determine whether the mitogenic activity of Ox-LDL is
due to its direct effect on macrophage growth, or due to its indirect effect through induction of certain growth factors, we first tested the
effect of medium exchange on Ox-LDL-induced cell growth of murine
peritoneal macrophages. Incubation with 20 µg/ml Ox-LDL for 5 days
without medium exchange induced a significant
[3H]thymidine incorporation (Fig.
1B). However, when macrophages were incubated with 20 µg/ml Ox-LDL for 5 days replacing the medium at day 1 or 2 by medium A containing the same concentration of Ox-LDL,
[3H]thymidine incorporation was markedly reduced by 75 or
60%, respectively (Fig. 1B). In contrast, replacement of
the medium at day 3 or 4 by medium A containing the same concentration
of Ox-LDL, did not change [3H]thymidine incorporation
(Fig. 1B). Cell-counting assay also showed that medium
exchange at day 1 or 2 significantly inhibited Ox-LDL-induced
macrophage growth (Table I). These
results suggest that a soluble factor(s) released from these cells into
the medium during day 1 to 2 may be involved in the induction of
macrophage growth by Ox-LDL.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of medium exchange on Ox-LDL-induced
macrophage growth. A, experimental protocol. Medium was
replaced at indicated time intervals ( ). B, peritoneal
macrophage monolayers from DDY mice (5 × 104
cells/well in 24-well tissue culture plates) were incubated in 1 ml of
medium A with or without 20 µg/ml Ox-LDL. At indicated times (days 1, 2, 3, and 4), cultured wells were replaced with 1 ml of medium A
containing the same concentration of Ox-LDL and incubated for a total
of 5 days. During the last 18 h of incubation, cells in each well
were chased with [3H]thymidine, harvested, and cellular
radioactivity was determined as described under "Experimental
Procedures." Data represent the mean ± S.D. of three
experiments.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Effect of medium exchange on Ox-LDL-induced macrophage growth
determined by cell counting assay
Peritoneal macrophage monolayers from DDY mice (5 × 104
cells/well in 24-well tissue culture plates) were incubated in 1 ml of
medium A with or without 20 µg/ml Ox-LDL. At indicated time intervals
(days 1, 2, 3, and 4), cultured wells were replaced by 1 ml of medium A
containing the same amount of Ox-LDL and incubated for a total 7 days.
On day 7, the number of cells was counted as described under
"Experimental Procedures." Data are expressed as mean ± S.D.
of triplicate counts. Percentages of control value (medium alone) are
expressed in parentheses.
|
|
Effect of Antibodies against GM-CSF on Ox-LDL-induced Macrophage
Growth--
Three types of cytokines are known to stimulate the growth
of monocytes or macrophages, including M-CSF (21, 22), GM-CSF (23, 24),
and IL-3 (25). Furthermore, a receptor for IL-5 is also known to share
a -subunit in common with those for GM-CSF and IL-3 (42, 43). To
determine which factor is responsible for Ox-LDL-induced macrophage
growth, we next examined neutralizing antibodies against these factors
for their effect on Ox-LDL-induced macrophage growth. Our preliminary
experiments showed that non-immune goat immunoglobulin G (IgG) had a
minimal nonspecific effect on Ox-LDL-induced macrophage growth when
compared with that of murine, rat, and rabbit (data not shown). We
therefore used anti-cytokine antibodies raised in goats in the present
study. Anti-M-CSF, anti-IL-3, and anti-IL-5 antibodies as well as goat
non-immune IgG had no effect on Ox-LDL-induced
[3H]thymidine incorporation, whereas anti-GM-CSF antibody
significantly suppressed it by 80% in a dose-dependent
manner (Fig. 2A). The cell-counting assay also showed that Ox-LDL-induced increase in the
cell number was suppressed by 87% by 10 µg/ml neutralizing antibody
against GM-CSF, while other neutralizing antibodies did not show
inhibitory effects (Table II). Although
detailed experiments will be shown later (Fig. 7), the neutralizing
activity of each antibody was verified by assessing its inhibitory
effect on the corresponding cytokine-induced
[3H]thymidine incorporation. In fact, the capacity of
recombinant murine GM-CSF to induce [3H]thymidine
incorporation into macrophages under the present culture conditions was
completely inhibited by the presence of 10 µg/ml anti-murine GM-CSF
antibody (data not shown). Similarly, the capacities of recombinant
murine M-CSF and recombinant murine IL-3 to induce [3H]thymidine incorporation were effectively neutralized
by respective antibodies (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of neutralizing antibodies against
GM-CSF, M-CSF, IL-3, and IL-5 on Ox-LDL-induced growth of macrophages
obtained from DDY mice (A) or FcR /Fc RII
double-knockout mice (B). A, peritoneal
macrophage monolayers from DDY mice (5 × 104
cells/well in 24-well tissue culture plates) were incubated for 5 days
without Ox-LDL ( ) or with 20 µg/ml Ox-LDL in 1 ml of medium A in
the presence of indicated concentrations of anti-GM-CSF antibody ( ),
anti-M-CSF antibody ( ), anti-IL-3 antibody ( ), anti-IL-5 antibody
( ), or non-immune IgG ( ). During the last 18 h of
incubation, cells in each well were chased with
[3H]thymidine, harvested, and radioactivity was
determined as described under "Experimental Procedures." Data
represent the mean ± S.D. of three experiments. B,
peritoneal macrophage monolayers from FcR /Fc RII double-knockout
mice (5 × 104 cells/well in 24-well tissue culture
plates) were incubated for 5 days with 20 µg/ml Ox-LDL in 1 ml of
medium A in the presence of 10 µg/ml anti-GM-CSF antibody, anti-M-CSF
antibody, anti-IL-3 antibody, non-immune IgG, or 20 µg/ml anti-IL-5
antibody. During the last 18 h of incubation, cells in each well
were chased with [3H]thymidine, harvested, and cellular
radioactivity was determined as described under "Experimental
Procedures." Data represent the mean ± S.D. of three
experiments.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Effects of neutralizing antibodies against GM-CSF, M-CSF, IL-3, and
IL-5 on Ox-LDL-induced macrophage growth determined by cell counting
assay
Peritoneal macrophage monolayers from DDY mice or FcR /Fc RII
double-knockout mice (5 × 104 cells/well in 24-well
tissue culture plates) were incubated for 7 days with 20 µg/ml Ox-LDL
in 1 ml of medium A in the presence of 10 µg/ml anti-GM-CSF antibody,
anti-M-CSF antibody, anti-IL-3 antibody, non-immune IgG or 20 µg/ml
of anti-IL-5 antibody. On day 7, the number of cells was counted as
described under "Experimental Procedures." Data are expressed as
mean ± S.D. of triplicate counts. Percentages of control value
(medium alone) are expressed in parentheses.
|
|
Another possibility taken into consideration is that, since macrophages
express receptors for IgG (Fc receptors), the neutralizing antibody
against GM-CSF could affect Fc receptors rather than neutralize the
GM-CSF activity. To test this, we determined the effect of anti-GM-CSF
antibody on Ox-LDL-induced growth of macrophages obtained from
FcR /Fc RII double-knockout mice lacking all the receptors for IgG
(28, 29). Ox-LDL-induced cell growth of macrophages from
FcR /Fc RII double-knockout mice was significantly inhibited by
anti-GM-CSF antibody but not by other antibodies when assayed both by
[3H]thymidine incorporation (Fig. 2B) and by
the cell-counting assay (Table II). These results indicate that the
inhibitory effect of anti-GM-CSF antibody on Ox-LDL-induced macrophage
growth is not due to its nonspecific action on the Fc receptors of
macrophages, but due largely to its neutralizing effect on GM-CSF
released from macrophages into the culture medium.
Macrophage mRNA Expression of GM-CSF, M-CSF, IL-3, and IL-5
Induced by Ox-LDL--
RT-PCR analyses were next performed to examine
whether Ox-LDL can increase mRNA levels of GM-CSF, M-CSF, IL-3, and
IL-5 with mRNA of -actin as a control. When macrophages were
incubated with medium A alone, GM-CSF mRNA was not detected during
the 7-h incubation (Fig. 3A, left
upper panel), whereas incubation with 40 µg/ml Ox-LDL for 30 min
resulted in the appearance of a 368-base pair band of GM-CSF (Fig.
3A, right upper panel). The maximal level of GM-CSF mRNA
was noted at 1 h after the addition of Ox-LDL, followed by a
time-dependent decrease (Fig. 3A, right upper
panel). In contrast to GM-CSF, neither M-CSF nor IL-3 was detected
as clear bands even after incubation of macrophages with 40 µg/ml Ox-LDL (Fig. 3A, right panel). However, the primer pairs
specific for M-CSF could detect a 578-base pairs band of M-CSF in total RNA of SR-4987 cells which were known to express a high level of M-CSF
mRNA (Fig. 3A, left side, middle upper panel). The
primer pairs specific for IL-3 could also detect a 423-base pairs band of IL-3 using total RNA of WEHI-3 cells, positive control cells for
murine IL-3 mRNA expression (Fig. 3A, left side, middle
panel). These results support the notion that each primer pair can
detect mRNA of each cytokine if detectable amounts of M-CSF or IL-3
mRNA are transcribed. mRNA levels of -actin as a control for
each control cell line (SR-4987 cells and WEHI-3 cells) were
indistinguishable from those of murine macrophages (data not shown). In
contrast to M-CSF and IL-3, a significant expression of IL-5 mRNA
was observed even when macrophages were incubated with medium alone,
and its level was gradually decreased with incubation time up to 7 h (Fig. 3A, left side, middle lower panel). However, levels
of IL-5 mRNA were not affected by incubation with Ox-LDL (Fig.
3A, right side, middle lower panel), under which mRNA
levels of -actin did not change (Fig. 3A, right lower
panel). Ox-LDL caused a dose-dependent increase of
GM-CSF mRNA at 1 h after its addition (Fig. 3B, upper panel), while the level of -actin mRNA was not affected by
Ox-LDL (Fig. 3B, lower panel). Thus, from the studies with
neutralizing antibodies (Fig. 2) as well as those of RT-PCR (Fig. 3), a
cytokine involved in the Ox-LDL-induced macrophage proliferation is
likely to be GM-CSF.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 3.
Time- and dose-dependent effect
of Ox-LDL on GM-CSF mRNA expression in macrophages determined by
RT-PCR (A and B) and by Northern blot
(C). Peritoneal macrophages from DDY mice (2 × 106) were seeded in 3.5-cm dish and incubated for 90 min.
A, the cell monolayers thus formed were incubated in 2 ml of
medium A with (right panel) or without (left
panel) 40 µg/ml Ox-LDL. After incubation for indicated time
periods (0, 0.5, 1, 3, 5, and 7 h), total RNA was extracted from
each dish with TRIzol. The expression of mRNA for GM-CSF
(upper panel), M-CSF (middle upper panel), IL-3
(middle panel), IL-5 (middle lower panel), or
-actin (lower panel) was evaluated by RT-PCR as described
under "Experimental Procedures." M indicates molecular
size marker. C indicates a positive control for each
cytokine: for M-CSF, SR-4987 cell-derived total RNA; and for IL-3,
WEHI-3 cell-derived total RNA, respectively. B, the cell
monolayers were incubated in 2 ml of medium A with the indicated
concentrations of Ox-LDL (0, 5, 10, 20, and 40 µg/ml) for 1 h
and total RNA was prepared from each dish with TRIzol. Total RNA was
also prepared from macrophage monolayers before incubation with Ox-LDL
as a control (P). The expression of GM-CSF mRNA
(upper panel) or -actin (lower panel) was
evaluated by RT-PCR as described under "Experimental Procedures."
M indicates molecular size marker. C, the
macrophage monolayers (2 × 106) in 3.5-cm dish were
incubated with or without 40 µg/ml Ox-LDL for 1 h and total RNA
was prepared. Ten µg/lane of total RNA was fractionated by
electrophoresis and transferred to Hybond-N+ nylon
membrane. The membrane was hybridized with 32P-labeled
GM-CSF-specific probe at 42 °C, and visualized as described under
"Experimetnal Procedures." To determine the amounts of total RNA
per lane, 28 S and 18 S RNA were stained after electrophoresis with
ethidium bromide and visualized by UV excitation (lower
panel). bp, base pair(s); kb, kilobasees.
|
|
The result obtained by RT-PCR analysis for GM-CSF was confirmed by
Northern blot analysis of total RNA of macrophages obtained after a 1-h
incubation with Ox-LDL. To determine the amounts of total RNA per lane,
28 S and 18 S RNA were stained after electrophoresis by ethidium
bromide and visualized by UV excitation (Fig. 3C, lower
panel). As shown in the upper panel of Fig.
3C, 32P-labeled GM-CSF cDNA probe
cross-hybridized with RNAs obtained from macrophages after a 1-h
incubation with 40 µg/ml Ox-LDL, with strong signals at 3.9, 3.0, and
1.2 kilobases.
Ox-LDL Induces GM-CSF Secretion from Macrophages--
In the next
step, we determined whether Ox-LDL could induce GM-CSF secretion from
macrophages. As shown in Fig.
4A, the addition of Ox-LDL at
>10 µg/ml significantly induced the secretion of GM-CSF. The
concentrations of GM-CSF in the medium reached a peak level at 4 h, followed by a time-dependent decrease to 48 h. The highest concentration of GM-CSF (2 pM) occurred at 4 h, produced by using 40 µg/ml Ox-LDL (Fig. 4A). In
contrast, when macrophages were incubated with medium A alone, GM-CSF
in medium showed a slight increase and reached basal level at 48 h
(Fig. 4A). When macrophages were incubated with 40 µg/ml
LDL or acetyl-LDL, the concentration of GM-CSF did not significantly
change compared with medium alone (data not shown). These results
suggested that induction of GM-CSF in these macrophages is specific for
Ox-LDL. The inset of Fig. 4A indicated that
Ox-LDL induced GM-CSF secretion from macrophages in a
dose-dependent manner. Upon incubation of macrophages with
Ox-LDL for more than 48 h (up to 120 h), we did not observe
GM-CSF secretion in the medium during the extended incubation (data not
shown). Therefore, these results when those of RT-PCR and Northern blot
analyses (Fig. 3) are combined, indicate that the increase in GM-CSF
mRNA by Ox-LDL is linked to the subsequent release of GM-CSF
protein into the medium.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 4.
Ox-LDL-induced GM-CSF release
(A), PKC activation (B), and effect of
calphostin C on Ox-LDL-induced GM-CSF release from macrophages
(C). A, peritoneal macrophage monolayers
from DDY mice (5 × 106) in a 10-cm dish were
incubated in 15 ml of medium A in the absence ( ) or presence of 10 µg/ml ( ), 20 µg/ml ( ), and 40 µg/ml ( ) of Ox-LDL.
Aliquots (300 µl) of the culture medium were taken at various time
intervals (0, 2, 4, 12, 24, and 48 h) and the supernatants were
obtained by brief centrifugation and frozen at 80 °C until
determination. After completion of all culture experiments, the frozen
culture supernatants were thawed and the level of GM-CSF was determined
by ELISA as described under "Experimental Procedures." The replot
of the concentrations of GM-CSF secreted at 4 h against Ox-LDL
concentrations was shown in the inset. B,
peritoneal macrophage monolayers from DDY mice (5 × 106) in a 10-cm dish were incubated for the indicated times
in 15 ml of serum-free RPMI 1640 in the presence of 40 µg/ml of LDL
( ), acetyl-LDL ( ), or Ox-LDL ( ). The membrane-associated PKC
activity was determined as described under "Experimental
Procedures." C, peritoneal macrophage monolayers from DDY
mice (5 × 106) in a 10-cm dish were incubated in 15 ml of medium A with ( ) or without ( ) 40 µg/ml Ox-LDL in the
presence of indicated concentrations of calphostin C. Aliquots (300 µl) of the culture medium were taken at 4 h after incubation
with Ox-LDL. The supernatants were obtained by brief centrifugation and
the level of GM-CSF was determined by ELISA as described under
"Experimental Procedures." Data represent the mean ± S.D. of
three experiments.
|
|
Our pervious study demonstrated that PKC activation by Ox-LDL is
important for Ox-LDL-induced macrophage growth (19). Consistent with
this notion, incubation with 40 µg/ml Ox-LDL significantly increased
membrane PKC activity with a peak time at 10 min, whereas LDL or
acetyl-LDL did not show such an effect (Fig. 4B). In the next step, to evaluate a role of PKC in Ox-LDL-induced GM-CSF production, we tested the effect of calphostin C, a well known PKC
inhibitor. As shown in Fig. 4C, Ox-LDL-induced increase in GM-CSF release was effectively inhibited by calphostin C in a dose-dependent manner; the extent of its inhibition was
>95% at 500 nM calphostin C which corresponded to that of
medium alone, suggesting involvement of certain types of PKC activation
in Ox-LDL-induced GM-CSF production.
Ox-LDL-induced GM-CSF Production by Macrophages Obtained from
MSR-AI/AII Knockout Mice--
To characterize the role of MSR-AI/AII
in Ox-LDL-induced GM-CSF production, Ox-LDL-induced GM-CSF secretion
from macrophages obtained from MSR-AI/AII-knockout mice was compared
with macrophages from wild-type littermates. As shown in Fig.
5, the level of GM-CSF release induced by
Ox-LDL from MSR-AI/AII-knockout macrophages was reduced by 73% when
compared with that from their wild-type littermates. It is therefore
likely that like Ox-LDL-induced macrophage proliferation, MSR-AI/AII
also plays a crucial role in Ox-LDL-induced GM-CSF production.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Ox-LDL-induced GM-CSF secretion from
macrophages obtained from MSR-AI/AII-knockout mice. Peritoneal
macrophages obtained from MSR-AI/AII-knockout mice (B) or
their wild-type littermates (A) (5 × 106)
in a 10-cm dish were incubated in 15 ml of medium A in the absence
(open column) or presence (hatched column) of 40 µg/ml Ox-LDL. Aliquots (300 µl) of the culture medium were taken at
4 h after incubation with Ox-LDL. The supernatants were obtained
by brief centrifugation and the level of GM-CSF was determined by ELISA
as described under "Experimental Procedures." Data represent the
mean ± S.D. of three experiments.
|
|
Effect of PLA2-treated Acetyl-LDL on GM-CSF
Production--
Our previous studies showed that MSR-mediated specific
uptake of lyso-PC of modified LDLs is a major pathway to induce
macrophage growth (12, 14, 18, 44). To know whether this was also the
case with Ox-LDL-induced GM-CSF production, we determined PLA2-treated acetyl-LDL for its effect on GM-CSF
production. Our PLA2-treated acetyl-LDL preparation indeed
showed the mitogenic activity for macrophages when assessed
both by [3H]thymidine
incorporation (8.8-fold increase above control, Fig. 6A) and
by the cell-counting (Table III).
Incubation with 40 µg/ml PLA2-treated acetyl-LDL for 30 min resulted in the appearance of the 368-base pair band of GM-CSF
(Fig. 6B, upper panel). The maximal expression of GM-CSF
mRNA was noted at 1 h after the addition of
PLA2-treated acetyl-LDL, followed by a
time-dependent decrease (Fig. 6B, upper panel).
Under the conditions, levels of -actin mRNA were not affected by
PLA2-treated acetyl-LDL (Fig. 6B, lower panel).
The addition of PLA2-treated acetyl-LDL at 40 µg/ml
significantly induced the secretion of GM-CSF; its concentrations in
the medium reached a peak level at 4 h, followed by a
time-dependent decrease to 48 h (Fig. 6C).
These patterns for increases in GM-CSF mRNA (Fig. 6B, upper
panel) and protein release (Fig. 6C) by
PLA2-treated acetyl-LDL were closely similar to those by
Ox-LDL (Figs. 3A, right panel, and
4A). Incubation of these macrophages with 100 µM palmitoyl-lysophosphatidylcholine alone or with 40 µg/ml acetyl-LDL for 4 h, instead of PLA2-treated
acetyl-LDL, did not lead to a significant GM-CSF release into the
medium (inset of Fig. 6C). These results suggest
that an effective uptake of lyso-PC of Ox-LDL is also important for
induction of GM-CSF.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of PLA2-treated acetyl-LDL
on GM-CSF production by macrophages. A, peritoneal
macrophage monolayers from DDY mice (5 × 104
cells/well in 24-well tissue culture plates) were incubated for 5 days
in 1 ml of medium A with or without 40 µg/ml PLA2-treated
acetyl-LDL, non-treated acetyl-LDL, or Ox-LDL in 1 ml of medium A. During the last 18 h of incubation, cells in each well were chased
with [3H]thymidine, harvested, and radioactivity was
determined as described under "Experimental Procedures." Data
represent the mean ± S.D. of three experiments. B,
peritoneal macrophage monolayers from DDY mice (2 × 106) in a 3.5-cm dish were incubated in 2 ml of medium A
with or without 40 µg/ml PLA2-treated acetyl-LDL. After
incubation for the indicated time periods (0, 0.5, 1, 3, 5, and 7 h), total RNA was extracted from each dish with TRIzol. The expression
of mRNA for GM-CSF (upper panel) or -actin
(lower panel) was evaluated by RT-PCR as described under
"Experimental Procedures." C, peritoneal macrophage
monolayers from DDY mice (5 × 106) in a 10-cm dish
were incubated in 15 ml of medium A in the absence ( ) or presence of
40 µg/ml non-treated acetyl-LDL ( ), PLA2-treated
acetyl-LDL ( ), and Ox-LDL ( ). The level of GM-CSF was determined
by ELISA as described in the legend to Fig. 4. Data represent the
mean ± S.D. of three experiments. The concentrations of GM-CSF
secreted at 4 h by 100 µM palmitoyl lyso-PC or 40 µg/ml acetyl-LDL was shown in the inset.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Effects of PLA2-treated acetyl-LDL on macrophage growth
determined by cell counting assay
Peritoneal macrophage monolayers from DDY mice (5 × 104
cells/well in 24-well tissue culture plates) were incubated for 7 days
with 20 µg/ml acetyl-LDL, PLA2-treated acetyl-LDL, or Ox-LDL
in 1 ml of medium A. On day 7, the number of cells was counted as
described under "Experimental Procedures." Data are expressed as
mean ± S.D. of triplicate counts. Percentages of control value
(medium alone) are expressed in parentheses.
|
|
Effect of Recombinant Murine GM-CSF on Macrophage Growth--
The
above results strongly suggested that an increase in GM-CSF at mRNA
level plays a crucial role in Ox-LDL-induced murine macrophage growth.
To confirm these findings, we examined the effect of recombinant murine
GM-CSF on murine macrophage growth. Incubation of macrophages with 1 pM recombinant GM-CSF led to a significant increase in
[3H]thymidine incorporation (2,058 cpm/well). In
addition, [3H]thymidine incorporation induced by >10
pM recombinant GM-CSF reached a plateau level (12,000 cpm/well at 10 pM) (Fig. 7).
Under our experimental conditions, incubation of these macrophages with 1 pM recombinant murine GM-CSF did not lead to a
significant increase in cell number when determined by the
cell-counting assay. Parallel incubation at concentrations higher than
1 nM showed a significant increase in the cell number
(Table IV).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of recombinant murine GM-CSF on
macrophage growth. Peritoneal macrophage monolayers from DDY mice
(5 × 104 cells/well in 24-well tissue culture plates)
were incubated for 5 days in 1 ml of medium A at indicated
concentrations of recombinant GM-CSF ( ). Parallel incubations were
performed with identical concentrations of M-CSF ( ), IL-3 ( ), and
IL-5 ( ). During the last 18 h of incubation, cells in each well
were chased with [3H]thymidine, harvested, and the
radioactivity was determined as described under "Experimental
Procedures." Data represent the mean ± S.D. of three
experiments.
|
|
View this table:
[in this window]
[in a new window]
|
Table IV
Effect of recombinant GM-CSF on macrophage growth determined by cell
counting assay
Peritoneal macrophage monolayers from DDY mice (5 × 104
cells/well in 24-well tissue culture plates) were incubated for 7 days
in the absence (medium alone) or presence of indicated concentrations
(1 pM, 10 pM, 100 pM, 1 nM, and 5 nM) of recombinant GM-CSF. On day 7, the number of cells was counted as described under "Experimental
Procedures." Data are expressed as mean ± S.D. of triplicate
counts. Percentages of control value (medium alone) are expressed in
parentheses.
|
|
 |
DISCUSSION |
Rajavashisth et al. (45) reported that minimally
oxidized LDL induced expression of GM-CSF mRNA in vivo
as well as endothelial cells in vitro. Although our present
results obtained by macrophages may be related to their study, the
interaction of Ox-LDL with macrophages seems to differ in nature from
that of minimally oxidized LDL with endothelial cells. Minimally
oxidized LDL is thought to be taken up by endothelial cells mainly
through the LDL receptor pathway (7), whereas our Ox-LDL preparation,
extensively oxidized LDL, is taken up by macrophages mainly through the
scavenger receptor pathway (2, 3). In other words, minimally oxidized
LDL is not recognized by the scavenger receptor (7), while Ox-LDL is
not recognized by the LDL receptor (2, 3). Thus, one possible
interpretation of our present result and their previous result would be
that the receptor-mediated delivery of oxidatively modified LDL to
endosomes and lysosomes may be important for induction of GM-CSF
mRNA. This notion is supported by the recent finding by Nagy
et al. (46), which shows that 9-hydroxyoctadecadienoic acid
and 13-hydroxyoctadecadienoic acid generated by lysosomal processing of
Ox-LDL are able to enhance expressions of several genes including CD36
by binding to peroxisome proliferator activated receptor in human
monocytes and human monocytic THP-1 cells. Alternatively, the mechanism
for GM-CSF induction by Ox-LDL in macrophages could be totally
different from that induced by minimally oxidized LDL in endothelial
cells.
GM-CSF is a well defined cytokine with a wide variety of potential
effects on proliferation, maturation, and various function of
monocytes/macrophages (47). Wang et al. (48) reported that GM-CSF and M-CSF expression is associated with macrophage proliferation in progressing rabbit atheromatous lesions, suggesting an atherogenic role of GM-CSF endogenously expressed in atherosclerotic lesions. This
notion may be consistent with the present finding that GM-CSF serves as
a priming factor in Ox-LDL-induced macrophage proliferation.
In contrast to GM-CSF, the definite role of M-CSF in the progression of
atherosclerosis is more generally accepted (1). In fact, Rosenfeld
et al. (49) demonstrated the expression of M-CSF both at
mRNA and protein levels in atherosclerotic lesions from humans,
WHHL, and cholesterol-fed rabbits. In particular, M-CSF mRNA and
its protein were demonstrated in macrophage-derived foam cells freshly
isolated from balloon injury-induced atherosclerotic lesions of
cholesterol-fed rabbits. Since recombinant M-CSF in fact increased the
[3H]thymidine incorporation into macrophages (Fig. 7),
M-CSF produced by macrophage-derived foam cells may induce macrophage
growth in a paracrine or autocrine fashion in atherosclerotic lesions. However, the present study showed that M-CSF gene expression was not
increased by Ox-LDL in macrophages (Fig. 3A, right panel) and that anti-M-CSF antibody had no inhibitory effect on Ox-LDL-induced macrophage growth (Fig. 2 and Table II), indicating that M-CSF is
unlikely to be involved in Ox-LDL-induced macrophage growth. This
notion is supported by a report by Clinton et al. (50) in
which M-CSF mRNA expression in both cultured human vascular endothelial cells and smooth muscle cells was significantly increased in vitro by endotoxin, human IL-1 , or tumor necrosis
factor , but not by Ox-LDL. Therefore, using the present data taken
together, it is unlikely that M-CSF plays a crucial role in
Ox-LDL-induced macrophage proliferation in vitro.
The size of murine GM-CSF mRNA reported by Gough et al.
(51) was 1.2 kilobases. Two additional strong signals (3.9 and 3.0 kilobases) were detected in our system (Fig. 3C). It is not
clear at present whether these signals really correspond to GM-CSF
mRNA. Since we used 32P-labeled murine GM-CSF cDNA
as a probe which was verified by dideoxy termination method, such
signals probably correspond to GM-CSF mRNA or unknown RNAs with a
high homology to GM-CSF. However, a possible contamination of the
genomic DNA is unlikely because parallel preparation of total RNA from
macrophages after incubation with the medium alone did not show such
3.9- and 3.0-kilobases signals.
In addition to MSR-AI/AII, several membrane proteins such as
Fc RII-B2, SR-BI, macrosialin/CD68, CD36, and LOX-1 have been proposed as Ox-LDL receptors (52). Extents of contribution of MSR-AI/AII to endocytic uptake of Ox-LDL is somewhat deviated from one
experiment to another, even though the results were obtained by using
the same source of MSR-AI/AII-knockout mice. According to a recent
report by Lougheed et al. (53), endocytic uptake of Ox-LDL
by peritoneal macrophages from knockout mice was decreased only by
30%, indicating endocytic uptake of Ox-LDL mainly depends on receptors
other than MSR-AI/AII. However, our previous study clearly showed that
the cell association of Ox-LDL with MSR-AI/AII-knockout macrophages was
reduced by >70% compared with that with their wild-type macrophages
(18). Our subsequent study also showed that the capacity of peritoneal
macrophages from MSR-AI/AII-knockout mice to degrade Ox-LDL was reduced
to 50% of that of wild-type littermates (30). This difference in
contribution of MSR-AI/AII might be derived from differences in ligand
preparations and/or culture conditions. Based on our own experiments
(18, 30), however, it seems reasonable to conclude that MSR-AI/AII
serves as one of the major pathways for endocytic degradation of
Ox-LDL. Therefore, a significant reduction in Ox-LDL-induced GM-CSF
release from MSR-AI/AII-knockout macrophages (Fig. 5) is largely
explained by the reduction in the uptake of Ox-LDL through
MSR-AI/AII.
Phorbol 12-myristate 13-acetate and A23187 (a calcium ionophore) are
reported to increase GM-CSF mRNA levels through activation of PKC
in human Jurkat T cell line (54). The recent report from this
laboratory demonstrated that Ox-LDL initiated an increase in
intracellular Ca2+ and subsequent activation of PKC within
10 min after incubation with macrophages (19). This notion was also
supported by the present study (Fig. 4B) and effective
inhibition of calphostin C for Ox-LDL-induced GM-CSF release into the
medium (Fig. 4C). It is therefore likely that PKC activation
by Ox-LDL increases GM-CSF mRNA in macrophages. In addition to this
pathway, the recent study by Martens et al. (20) showed the
involvement of the phosphatidylinositol 3-OH kinase pathway in the
Ox-LDL-induced macrophage growth. Our preliminary experiments showed
that phosphatidylinositol 3-OH kinase inhibitors such as wortmannin and
LY294002 had no appreciable effect on Ox-LDL-induced GM-CSF release
from macrophages,2 suggesting
that Ox-LDL-induced GM-CSF release is independent of
phosphatidylinositol 3-OH kinase activation.
One important point indicated by the present study is the involvement
of a cytokine(s) other than GM-CSF in murine macrophage growth. When
macrophages were incubated with Ox-LDL, GM-CSF was promptly secreted
into the medium with a maximal peak at 4-6 h but rapidly decreased to
almost basal level at 24 h (Fig. 4). However, replacement of
culture medium at 24 h after incubation with Ox-LDL by a fresh
medium containing the same concentration of Ox-LDL resulted in a marked
reduction of the growth-stimulating effect of Ox-LDL (Fig. 1 and Table
I). If the macrophage growth was only explained by a direct cellular
interaction of GM-CSF alone, such medium exchange should not influence
Ox-LDL-induced macrophage growth (since the culture medium obtained
24 h after incubation with Ox-LDL contained only a basal level of
GM-CSF). A simplest interpretation of this finding would be that, in
addition to GM-CSF, another factor(s) also participates in
Ox-LDL-induced macrophage growth. This soluble factor can still be
present in the medium even 24 h after incubation of macrophages
with Ox-LDL, and is removed by the replacement of the original medium
with a fresh medium, leading to a significant inhibition of macrophage growth. Since the increase in mRNA of several cytokines was
determined within 7 h after Ox-LDL addition (Fig. 3A),
it is possible to speculate that certain cytokines represented by
GM-CSF induced initially by Ox-LDL may then interact with macrophages,
leading to the induction of M-CSF, IL-3, IL-5, and other cytokines at the later stage, which could play some role in the macrophage growth.
Further studies are needed to identify this factor.
Recombinant murine GM-CSF at 1 pM exhibited a significant
increase in [3H]thymidine incorporation in macrophages
(Fig. 7), but did not increase the cell number under identical
conditions (Table IV). The concentration required for producing a
significant increase in the cell number was 1 nM (Table
IV), about 1,000 times higher than that required for a significant
thymidine incorporation (Fig. 7). However, the concentration of GM-CSF
released from macrophages upon incubation with Ox-LDL was 1-2
pM (Fig. 4A). Thus, GM-CSF induced by Ox-LDL
would be sufficient for macrophage DNA synthesis but inadequate to
increase the number of macrophages. It is generally accepted that cell
growth is regulated by four phases of the cell cycle: G1,
S, G2, and M phase (55). Extensive studies using Saccharomyces cerevisiae have shown the presence of two
checkpoints in each phase (G1/S and G2/M
checkpoints) and both checkpoints must be driven forward for cell
division (55). Based on the results of the present study, it is likely
that GM-CSF is required for the first checkpoint, whereas another
cytokine(s) might act on the second checkpoint, from S phase to M
phase, thus leading finally to the growth of macrophages.
 |
ACKNOWLEDGEMENTS |
We are grateful to Drs. Hirofumi Matsuda,
Takeshi Matsumura, Toru Takemura, Takashi Kawano, Takashi Kawasaki,
Yuko Hasunuma, Yu-Ichiro Sakamoto, Guopin Wang, and Kyu Kyu Maung for
their collaborative endeavor throughout this study.
 |
FOOTNOTES |
*
This work was supported in part by Scientific Research
Grants-in-Aids 09877200, 09770789, 10671077, and 10877179 from the Ministry of Education, Science, Sports and Cultures of Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Dept. of Biochemistry,
Kumamoto University School of Medicine, Honjo 2-2-1, Kumamoto 860-0811, Japan. Tel. and Fax: 81-96-364-6940; E-mail:
horiuchi{at}gpo.kumamoto-u.ac.jp.
The abbreviations used are:
LDL, low density
lipoprotein; acetyl-LDL, acetylated LDL; Ox-LDL, oxidized LDL; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage
colony-stimulating factor; IL, interleukin; lyso-PC, lysophosphatidylcholine; MSR, macrophage scavenger receptor; ELISA, enzyme-linked immunosorbent assay; RT-PCR, reverse
transcription-polymerase chain reaction; PKC, protein kinase C.
2
T. Biwa, H. Hakamata, M. Sakai, A. Miyazaki, and
S. Horiuchi, unpublished observations.
 |
REFERENCES |
-
Ross, R.
(1993)
Nature
362,
801-809[CrossRef][Medline]
[Order article via Infotrieve]
-
Brown, M. S.,
and Goldstein, J. L.
(1983)
Annu. Rev. Biochem.
52,
223-261[CrossRef][Medline]
[Order article via Infotrieve]
-
Steinberg, D.,
Parthasarathy, S.,
Carew, T. E.,
Khoo, J. C.,
and Witztum, J. L.
(1989)
N. Engl. J. Med.
320,
915-924[Medline]
[Order article via Infotrieve]
-
Palinski, W.,
Rosenfeld, M. E.,
Ylä-Herttuala, S.,
Gurtner, G. C.,
Socher, S. S.,
Butler, S. W.,
Parthasarathy, S.,
Carew, T. E.,
Steinberg, D.,
and Witztum, J. L.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1372-1376[Abstract/Free Full Text]
-
Ylä-Herttuala, S.,
Palinski, W.,
Rosenfeld, M. E.,
Parthasarathy, S.,
Carew, T. E.,
Butler, S.,
Witztum, J. L.,
and Steinberg, D.
(1989)
J. Clin. Invest.
84,
1086-1095
-
Quinn, M. T.,
Parthasarathy, S.,
Fong, L. G.,
and Steinberg, D.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
2995-2998[Abstract/Free Full Text]
-
Berliner, J. A.,
Territo, M. C.,
Sevanian, A.,
Ramin, S.,
Kim, J. A.,
Bamshad, B.,
Esterson, M.,
and Fogelman, A. M.
(1990)
J. Clin. Invest.
85,
1260-1266
-
Frosteg
rd, J.,
Nilsson, J.,
Haegerstrand, A.,
Hamsten, A.,
Wigzell, H.,
and Gidlund, M.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
904-908[Abstract/Free Full Text] -
Quinn, M. T.,
Parthasarathy, S.,
and Steinberg, D.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
5949-5953[Abstract/Free Full Text]
-
Hakamata, H.,
Miyazaki, A.,
Sakai, M.,
Matsuda, H.,
Suzuki, H.,
Kodama, T.,
and Horiuchi, S.
(1998)
J. Lipid Res.
39,
482-494[Abstract/Free Full Text]
-
Yui, S.,
Sasaki, T.,
Miyazaki, A.,
Horiuchi, S.,
and Yamazaki, M.
(1993)
Arterioscler. Thromb.
13,
331-337[Abstract/Free Full Text]
-
Sakai, M.,
Miyazaki, A.,
Hakamata, H.,
Sasaki, T.,
Yui, S.,
Yamazaki, M.,
Shichiri, M.,
and Horiuchi, S.
(1994)
J. Biol. Chem.
269,
31430-31435[Abstract/Free Full Text]
-
Sato, Y.,
Kobori, S.,
Sakai, M.,
Yano, T.,
Higashi, T.,
Matumura, T.,
Molikawa, W.,
Terano, T.,
Miyazaki, A.,
Horiuchi, S.,
and Shichiri, M.
(1996)
Atherosclerosis
125,
15-26[CrossRef][Medline]
[Order article via Infotrieve]
-
Sakai, M.,
Miyazaki, A.,
Hakamata, H.,
Sato, Y.,
Matumura, T.,
Kobori, S.,
Shichiri, M.,
and Horiuchi, S.
(1996)
Arterioscler. Thromb. Vasc. Biol.
16,
600-605[Abstract/Free Full Text]
-
Gordon, D.,
Reidy, M. A.,
Benditt, E. P.,
and Schwartz, S. M.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4600-4604[Abstract/Free Full Text]
-
Rosenfeld, M. E.,
and Ross, R.
(1990)
Arteriosclerosis
10,
680-687[Abstract/Free Full Text]
-
Spagnoli, L. G.,
Orlandi, A.,
and Santeusanio, G.
(1991)
Atherosclerosis
88,
87-92[CrossRef][Medline]
[Order article via Infotrieve]
-
Sakai, M.,
Miyazaki, A.,
Hakamata, H.,
Kodama, T.,
Suzuki, H.,
Kobori, S.,
Shichiri, M.,
and Horiuchi, S.
(1996)
J. Biol. Chem.
271,
27346-27352[Abstract/Free Full Text]
-
Matsumura, T.,
Sakai, M.,
Kobori, S.,
Biwa, T.,
Takemura, T.,
Matsuda, H.,
Hakamata, H.,
Horiuchi, S.,
and Shichiri, M.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
3013-3020[Abstract/Free Full Text]
-
Martens, J. S.,
Reiner, N. E.,
Herrera-Velit, P.,
and Steinbrecher, U. P.
(1998)
J. Biol. Chem.
273,
4915-4920[Abstract/Free Full Text]
-
Stanley, E. R.,
Cifone, M.,
Heard, P. M.,
and Defendi, V.
(1976)
J. Exp. Med.
143,
631-647[Abstract/Free Full Text]
-
Stewart, C. C.,
and Lin, H.-S.
(1978)
J. Reticuloendothel. Soc.
23,
269-285[Medline]
[Order article via Infotrieve]
-
Chen, B. D.-M.,
Clark, C. R.,
and Chou, T.-H.
(1988)
Blood
71,
997-1002[Abstract/Free Full Text]
-
Chodakewitz, J. A.,
Kupper, T. S.,
and Coleman, D. L.
(1988)
J. Immunol.
140,
832-836[Abstract]
-
Chen, B. D.-M.,
and Clark, C. R.
(1986)
J. Immunol.
137,
563-570[Abstract]
-
Murakami, M.,
Horiuchi, S.,
Takata, K.,
and Morino, Y.
(1987)
J. Biochem. (Tokyo)
101,
729-741[Abstract/Free Full Text]
-
Suginohara, Y.,
Miyazaki, A.,
Hakamata, H.,
Sakamoto, Y.,
Ohta, T.,
Matsuda, I.,
and Horiuchi, S.
(1996)
Atherosclerosis
120,
167-179[CrossRef][Medline]
[Order article via Infotrieve]
-
Takai, T.,
Ono, M.,
Hikida, M.,
Ohmori, H.,
and Ravetch, J. V.
(1996)
Nature
379,
346-349[CrossRef][Medline]
[Order article via Infotrieve]
-
Takai, T.,
Li, M.,
Sylvestre, D.,
Clynes, R.,
and Ravetch, J. V.
(1994)
Cell
76,
519-529[CrossRef][Medline]
[Order article via Infotrieve]
-
Suzuki, H.,
Kurihara, Y.,
Takeya, M.,
Kamada, N.,
Kataoka, M.,
Jishage, K.,
Ueda, O.,
Sakaguchi, H.,
Higashi, T.,
Suzuki, T.,
Takashima, Y.,
Kawabe, Y.,
Cynshi, O.,
Wada, Y.,
Honda, M.,
Kurihara, H.,
Aburatani, H.,
Doi, T.,
Matsumoto, A.,
Azuma, S.,
Noda, T.,
Toyoda, Y.,
Itakura, H.,
Yazaki, Y.,
Horiuchi, S.,
Takahashi, K.,
Kruijt, J. K.,
Berkel, T. J. C.,
Steinbrecher, U. P.,
Ishibashi, S.,
Maeda, N.,
Gordon, S.,
and Kodama, T.
(1997)
Nature
386,
292-296[CrossRef][Medline]
[Order article via Infotrieve]
-
Pessina, A.,
Mineo, E.,
Neri, M. G.,
Gribaldo, L.,
Colombi, R.,
Brambilla, P.,
and Zaleskis, G.
(1992)
Cytotechnology
8,
93-102[CrossRef][Medline]
[Order article via Infotrieve]
-
Ralph, P.,
and Nakoinz, I.
(1977)
J. Immunol.
119,
950-954[Abstract/Free Full Text]
-
Sasaki, T.,
Horiuchi, S.,
Yamazaki, M.,
and Yui, S.
(1996)
Biol. Pharm. Bull.
19,
449-455[Medline]
[Order article via Infotrieve]
-
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
-
Lee, J. C.,
Hapel, A. J.,
and Ihle, J. N.
(1982)
J. Immunol.
128,
2393-2398[Abstract]
-
Miyatake, S.,
Otsuka, T.,
Yokota, T.,
Lee, F.,
and Arai, K.
(1985)
EMBO J.
4,
2561-2568[Medline]
[Order article via Infotrieve]
-
Ladner, M. B.,
Martin, G. A.,
Noble, J. A.,
Wittman, V. P.,
Warren, M. K.,
McGrogan, M.,
and Stanley, E. R.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
6706-6710[Abstract/Free Full Text]
-
Miyatake, S.,
Yokota, T.,
Lee, F.,
and Arai, K.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
82,
316-320
-
Campbell, H. D.,
Sanderson, C. J.,
Wang, Y.,
Hort, Y.,
Martinson, M. E.,
Tucker, W. Q. J.,
Stellwagen, A.,
Strath, M.,
and Young, I. G.
(1988)
Eur. J. Biochem.
174,
345-352[Medline]
[Order article via Infotrieve]
-
Alonso, S.,
Minty, A.,
Bourlet, Y.,
and Buckingham, M.
(1986)
J. Mol. Evol.
23,
11-22[CrossRef][Medline]
[Order article via Infotrieve]
-
Matsuda, H.,
Hakamata, H.,
Miyazaki, A.,
Sakai, M.,
Chang, C. C. Y.,
Chang, T.-Y.,
Koboli, S.,
Shichiri, M.,
and Horiuchi, S.
(1996)
Biochim. Biophys. Acta
1301,
76-84[Medline]
[Order article via Infotrieve]
-
Kitamura, T.,
Sato, N.,
Arai, K.,
and Miyajima, A.
(1991)
Cell
66,
1165-1174[CrossRef][Medline]
[Order article via Infotrieve]
-
Tavernier, J.,
Devos, R.,
Cornelis, S.,
Tuypens, T.,
Heyden, J. V.,
Fiers, W.,
and Plaetinck, G.
(1991)
Cell
66,
1175-1184[CrossRef][Medline]
[Order article via Infotrieve]
-
Sakai, M.,
Shichiri, M.,
Hakamata, H.,
and Horiuchi, S
(1998)
Trends Cardiovasc. Med.
8,
119-124
-
Rajavashisth, T. B.,
Andalibi, A.,
Territo, M. C.,
Berliner, J. A.,
Navab, M.,
Fogelman, A. M.,
and Lusis, A. J.
(1990)
Nature
344,
254-257[CrossRef][Medline]
[Order article via Infotrieve]
-
Nagy, L.,
Tontonoz, P.,
Alvarez, J. G. A.,
Chen, H.,
and Evans, R. M.
(1998)
Cell
93,
229-240[CrossRef][Medline]
[Order article via Infotrieve]
-
Gasson, J. C.
(1991)
Blood
77,
1131-1145[Free Full Text]
-
Wang, J.,
Wang, S.,
Lu, Y.,
Weng, Y.,
and Gown, A. M.
(1994)
Exp. Mol. Pathol.
61,
109-118[CrossRef][Medline]
[Order article via Infotrieve]
-
Rosenfeld, M. E.,
Ylä-Herttuala, S.,
Lipton, B. A.,
Ord, V. A.,
Witztum, J. L.,
and Steinberg, D.
(1992)
Am. J. Pathol.
140,
291-300[Abstract]
-
Clinton, S. K.,
Underwood, R.,
Hayes, L.,
Sherman, M. L.,
Kufe, D. W.,
and Libby, P.
(1992)
Am. J. Pathol.
140,
301-316[Abstract]
-
Gough, N. M.,
Gough, J.,
Metcalf, D.,
Kelso, A.,
Grail, D.,
Nicola, N. A.,
Burgess, A. W.,
and Dunn, A. R.
(1984)
Nature
309,
763-767[CrossRef][Medline]
[Order article via Infotrieve]
-
Kodama, T.,
Doi, T.,
Suzuki, H.,
Takahashi, K.,
Wada, Y.,
and Gordon, S.
(1996)
Curr. Opin. Lipidol.
7,
287-291[Medline]
[Order article via Infotrieve]
-
Lougheed, M.,
Lum, C. M.,
Ling, W.,
Suzuki, H.,
Kodama, T.,
and Steinbrecher, U.
(1997)
J. Biol. Chem.
272,
12938-12944[Abstract/Free Full Text]
-
Miyatake, S.,
Seiki, M.,
Yoshida, M.,
and Arai, K.
(1988)
Mol. Cell. Biol.
8,
5581-5587[Abstract/Free Full Text]
-
Hartwell, L. H.,
and Weinert, T. A.
(1989)
Science
246,
629-633[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. H. Chen, M. Riazy, E. M. Smith, C. G. Proud, U. P. Steinbrecher, and V. Duronio
Oxidized LDL-Mediated Macrophage Survival Involves Elongation Factor-2 Kinase
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2009;
29(1):
92 - 98.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ditiatkovski, B.-H. Toh, and A. Bobik
GM-CSF Deficiency Reduces Macrophage PPAR-{gamma} Expression and Aggravates Atherosclerosis in ApoE-Deficient Mice
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2006;
26(10):
2337 - 2344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, T. Taguchi, T. Matsuo, K. Sonoda, D. Kukidome, K. Imoto, T. Nishikawa, et al.
Statins Suppress Oxidized Low Density Lipoprotein-induced Macrophage Proliferation by Inactivation of the Small G Protein-p38 MAPK Pathway
J. Biol. Chem.,
February 25, 2005;
280(8):
6627 - 6633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Murata, A. Tanimoto, K.-Y. Wang, M. Tsutsui, Y. Sasaguri, F. De Corte, and H. Matsushita
Granulocyte Macrophage-Colony Stimulating Factor Increases the Expression of Histamine and Histamine Receptors in Monocytes/Macrophages in Relation to Arteriosclerosis
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2005;
25(2):
430 - 435.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Lamharzi, C. B. Renard, F. Kramer, S. Pennathur, J. W. Heinecke, A. Chait, and K. E. Bornfeldt
Hyperlipidemia in Concert With Hyperglycemia Stimulates the Proliferation of Macrophages in Atherosclerotic Lesions: Potential Role of Glucose-Oxidized LDL
Diabetes,
December 1, 2004;
53(12):
3217 - 3225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kobayashi, M. Suzuki, N. Kanayama, and T. Terao
Genetic Down-regulation of Phosphoinositide 3-Kinase by Bikunin Correlates with Suppression of Invasion and Metastasis in Human Ovarian Cancer HRA Cells
J. Biol. Chem.,
February 20, 2004;
279(8):
6371 - 6379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. B. Sedgwick, Y. S. Hwang, H. A. Gerbyshak, H. Kita, and W. W. Busse
Oxidized Low-Density Lipoprotein Activates Migration and Degranulation of Human Granulocytes
Am. J. Respir. Cell Mol. Biol.,
December 1, 2003;
29(6):
702 - 709.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Itabe, M. Mori, Y. Fujimoto, Y. Higashi, and T. Takano
Minimally Modified LDL Is an Oxidized LDL Enriched with Oxidized Phosphatidylcholines
J. Biochem.,
September 1, 2003;
134(3):
459 - 465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Hundal, A. Gomez-Munoz, J. Y. Kong, B. S. Salh, A. Marotta, V. Duronio, and U. P. Steinbrecher
Oxidized Low Density Lipoprotein Inhibits Macrophage Apoptosis by Blocking Ceramide Generation, Thereby Maintaining Protein Kinase B Activation and Bcl-XL Levels
J. Biol. Chem.,
June 27, 2003;
278(27):
24399 - 24408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Hamilton
Nondisposable materials, chronic inflammation, and adjuvant action
J. Leukoc. Biol.,
June 1, 2003;
73(6):
702 - 712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Hundal, B. S. Salh, J. W. Schrader, A. Gomez-Munoz, V. Duronio, and U. P. Steinbrecher
Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway
J. Lipid Res.,
September 1, 2001;
42(9):
1483 - 1491.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Hamilton, G. Whitty, and W. Jessup
Oxidized LDL Can Promote Human Monocyte Survival
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2000;
20
(10):
2329 - 2331.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Anthonsen, D. Stengel, D. Hourton, E. Ninio, and B. Johansen
Mildly Oxidized LDL Induces Expression of Group IIa Secretory Phospholipase A2 in Human Monocyte-Derived Macrophages
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2000;
20(5):
1276 - 1282.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Biwa, M. Sakai, T. Matsumura, S. Kobori, K. Kaneko, A. Miyazaki, H. Hakamata, S. Horiuchi, and M. Shichiri
Sites of Action of Protein Kinase C and Phosphatidylinositol 3-Kinase Are Distinct in Oxidized Low Density Lipoprotein-induced Macrophage Proliferation
J. Biol. Chem.,
February 25, 2000;
275(8):
5810 - 5816.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. J. de Winther, K. W. van Dijk, L. M. Havekes, and M. H. Hofker
Macrophage Scavenger Receptor Class A : A Multifunctional Receptor in Atherosclerosis
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2000;
20(2):
290 - 297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gomez-Munoz, J. S. Martens, and U. P. Steinbrecher
Stimulation of Phospholipase D Activity by Oxidized LDL in Mouse Peritoneal Macrophages
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2000;
20(1):
135 - 143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Matsumura, M. Sakai, K. Matsuda, N. Furukawa, K. Kaneko, and M. Shichiri
Cis-acting DNA Elements of Mouse Granulocyte/Macrophage Colony-stimulating Factor Gene Responsive to Oxidized Low Density Lipoprotein
J. Biol. Chem.,
December 31, 1999;
274(53):
37665 - 37672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Parthasarathy, N. Santanam, S. Ramachandran, and O. Meilhac
Oxidants and antioxidants in atherogenesis: an appraisal
J. Lipid Res.,
December 1, 1999;
40(12):
2143 - 2157.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sakai, T. Biwa, T. Matsumura, T. Takemura, H. Matsuda, Y. Anami, T. Sasahara, S. Kobori, and M. Shichiri
Glucocorticoid Inhibits Oxidized LDL-Induced Macrophage Growth by Suppressing the Expression of Granulocyte/Macrophage Colony-Stimulating Factor
Arterioscler. Thromb. Vasc. Biol.,
July 1, 1999;
19(7):
1726 - 1733.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Martens, M. Lougheed, A. Gomez-Munoz, and U. P. Steinbrecher
A Modification of Apolipoprotein B Accounts for Most of the Induction of Macrophage Growth by Oxidized Low Density Lipoprotein
J. Biol. Chem.,
April 16, 1999;
274(16):
10903 - 10910.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|